NASDAQ:TCON
TRACON Pharmaceuticals Stock News
$1.43
-0.100 (-6.54%)
At Close: May 17, 2024
TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
08:05am, Tuesday, 02'nd Mar 2021
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cance
TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q4 2020 Results - Earnings Call Transcript
05:36pm, Saturday, 27'th Feb 2021
TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q4 2020 Results - Earnings Call Transcript
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
04:03pm, Thursday, 25'th Feb 2021
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON to Report Fourth Quarter and Full Year 2020 Financial Results and Company Highlights on February 25, 2021
08:05am, Thursday, 18'th Feb 2021
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review
08:05am, Tuesday, 19'th Jan 2021
NDA was Submitted in November by TRACON's Corporate Partners, Alphamab Oncology and 3D Medicines, in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submitted in N
TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
08:05am, Wednesday, 06'th Jan 2021
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal
TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering
08:05am, Tuesday, 29'th Dec 2020
SAN DIEGO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON Pharmaceuticals Announces $8.8 Million Registered Direct Offering
08:05am, Tuesday, 22'nd Dec 2020
SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal Trial
08:05am, Thursday, 10'th Dec 2020
Company Expects Interim Data in Mid-2021 Company Expects Interim Data in Mid-2021
SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gas
TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q3 2020 Results - Earnings Call Transcript
10:32pm, Tuesday, 10'th Nov 2020
TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q3 2020 Results - Earnings Call Transcript
TRACON Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
04:03pm, Tuesday, 10'th Nov 2020
SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
TRACON to Report Third Quarter 2020 Financial Results and Company Highlights on November 10, 2020
08:05am, Tuesday, 03'rd Nov 2020
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer
